Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity, PSA Decline and Genetic Variation in Proteins Involved in Androgen Metabolism in Metastatic Hormone Naive Prostate Cancer

NCT03833921 is registered in ClinicalTrials.gov with Martha Mims as lead sponsor.

NCT NCT03833921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03833921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity, PSA Decline and Genetic Variation in Proteins Involved in Androgen Metabolism in Metastatic Hormone Naive Prostate Cancer
Lead sponsor
Martha Mims
Phase
Phase 2
Overall status
Recruiting
Start date
May 23, 2019
Completion date
April 30, 2038
Enrollment
130 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, prostate cancer metastatic